Page results
-
Online form for beginning the sefl referral process at UCLH maternity services.
-
We offer weekly neuro-rehabilitation assessment clinics where our patients are assessed by a multidisciplinary team.
-
This page is for patients who are going to receive whole brain radiotherapy to the brain if your cancer has spread there.
-
This page provides information for adolescent patients with inflammatory bowel disease.
-
Paediatric Audio-vestibular Medicine provides investigation, diagnosis and management of the medical aspect of disorders of hearing, balance and tinnitus in children. The service consists of a multi-professional team and is located at The Royal National ENT & Eastman Dental Hospitals, 47-49 Huntley Street London WC1E 6DG.
-
This page provides an overview of the Ambulatory Care Service for adult patients.
-
OPAT (Outpatient Parenteral Antimicrobial Therapy) is a safe and convenient way to receive intravenous (IV) antibiotic therapy at home or in a clinic.
-
Advice on eating better for young people living with fatigue-related conditions such as CFS and ME.
-
Radiotherapy Department Patient Information series no. 18 - prostate brachytherapy prostate high dose rate (HDR) brachytherapy
-
This information is for patients who are receiving radiotherapy to the prostate or prostate bed. It explains what the treatment involves, describes side-effects you may experience during and after treatment, and how best to cope with them.
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology